Novartis Exceeds Earnings and Revenue Estimates, Reaffirms FY26 Outlook
Novartis (NVS) reported Q2 non-GAAP earnings per share of $2.41, surpassing estimates by $0.26, with revenue reaching $14.41 billion, beating expectations by $350 million and growing 2.6% year-over-year. The company reaffirmed its full-year FY26 guidance for net sales growth.
Tickers: $NVS
Topics: Earnings Pharmaceuticals